Physician profile
Thomas M Ebersole
NPI 1710920236
$696.06
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $470 · 2020: $105 · 2021: $121.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $199.22 | 2019-2020 | |
| Pfizer INC. | $181.49 | 2019-2020 | |
| Abiomed | $121.34 | 2021 | |
| Astellas Pharma US INC | $51.51 | 2019 | |
| Hologic Sales and Service, LLC | $40.33 | 2020 | |
| Millicent US INC | $32.63 | 2019-2020 | |
| Roche Diagnostics Corporation | $15.17 | 2019 | |
| Covidien LP | $15.07 | 2020 | |
| Minerva Surgical, INC | $13.84 | 2019 | |
| Daiichi Sankyo INC. | $13.53 | 2019 | |
| Baxter Healthcare | $11.93 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Ebersole listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.